Drug Trial Radar · NCT06921928
Study for AZD4360 in Participants With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Apr 29, 2025
Primary completion
Mar 31, 2027
Study completion Dec 16, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
AZD4360Drug
Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360Time frame: Through study completion, up to approximately 2 years
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Santa Monica, California
Research Site
Providence, Rhode Island
Research Site
Houston, Texas
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Shanghai, China
Research Site
Wuhan, China
Research Site
Dresden, Germany
Research Site
Frankfurt, Germany
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Kōtoku, Japan
Research Site
Glasgow, United Kingdom
Research Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.